Versant Capital Management
STOK icon

Versant Capital Management’s Stoke Therapeutics STOK Stock Holding History

Versant Capital Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$46.1K Sell
1,773
-178
-9% -$5.38K ﹤0.01% 1455
2026
Q2 		$63.8K Buy
1,951
+359
+23% +$11.5K 0.01% 1197
2026
Q1 		$51.8K Hold
1,592
– – 0.01% 1215
2025
Q4 		$50.5K Hold
1,592
– – 0.01% 1087
2025
Q3 		$37.4K Hold
1,592
– – 0.01% 1200
2025
Q2 		$18.1K Buy
1,592
+1,032
+184% +$9.8K ﹤0.01% 1586
2025
Q1 		$3.72K Hold
560
– – ﹤0.01% 2133
2024
Q4 		$6.18K Buy
+560
New +$6.88K ﹤0.01% 1660

Other funds holding STOK

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
SYM Financial Corp
SYM Financial Corp Winona Lake, Indiana $1.31B AUM 18.92% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Moran Wealth Management
Moran Wealth Management Naples, Florida $3.64B AUM 28.63% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Harbor Capital Advisors
Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
Generali Investments Management
Generali Investments Management Ljubljana, Slovenia $517M AUM 27.81% 1-Year Est. Return

Versant Capital Management's STOK Position: Q3 2026 in Review

Versant Capital Management reduced its Stoke Therapeutics (STOK) stake by 9.1% in Q3 2026, selling an estimated $5.38K and leaving 1,773 shares worth $46.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1455.

Versant Capital Management first reported a position in STOK in Q4 2024 and has held it in 8 quarters since. The position peaked at $63.8K in Q2 2026. 39 funds tracked by Wall St. Rank hold STOK as of Q3 2026.

  • Versant Capital Management held 1,773 shares of Stoke Therapeutics worth $46.1K as of Q3 2026.
  • Versant Capital Management sold 178 Stoke Therapeutics shares in Q3 2026, an estimated $5.38K.
  • Stoke Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1455 holding.
  • Versant Capital Management first reported a position in Stoke Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • Versant Capital Management's Stoke Therapeutics position peaked at $63.8K in Q2 2026.
  • 39 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.